| Symbol |
SYP |
| Full Name |
Synaptophysin |
| Chromosome |
Xp11.23 |
| NCBI Gene |
6855 |
| Ensembl |
ENSG00000100391 |
| UniProt |
P21579 |
| Protein Length |
316 amino acids |
| Diseases |
[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Huntington's Disease, ALS |
| Expression |
Brain (cortex, hippocampus), cerebellum, retina, neuroendocrine cells |
Synaptophysin (Syp) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The SYP gene encodes Synaptophysin, a major synaptic vesicle glycoprotein essential for synaptic transmission.
SYNAPTOPHYSIN is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of SYNAPTOPHYSIN is associated with neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and related disorders.
Synaptophysin is the most abundant synaptic vesicle membrane protein, constituting up to 10% of all synaptic vesicle proteins. It plays critical roles in:
- Synaptic vesicle biogenesis and trafficking: Forms channels in synaptic vesicles that facilitate neurotransmitter release
- Neurotransmitter release: Regulates the fusion of synaptic vesicles with the presynaptic membrane
- Synapse formation: Essential for proper synaptic connectivity during development
- Calcium sensing: Interacts with synaptogyrin to regulate synaptic vesicle exocytosis
- Synaptophysin levels are significantly reduced in AD brains, correlating with cognitive decline
- Loss of synaptophysin-positive terminals is a hallmark of early AD
- Used as a biomarker for synaptic integrity in CSF
- Decreased synaptophysin expression in the substantia nigra
- Associated with dopaminergic neuron loss
High expression in:
- Cerebral cortex (especially layers II-III)
- Hippocampus (CA1-CA3 regions)
- Cerebellum
- Retina
- Wiedenmann B, Franke WW (1985). Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell. PMID:2578939
- Calhoun ME et al. (1996). Comparative evaluation of synaptophysin-based immunohistochemistry and image analysis of beta-amyloid in entorhinal cortex. J Neuropathol Exp Neurol. PMID:8786408
The study of Synaptophysin (Syp) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
¶ Structure and Function
Synaptophysin is a hexameric integral membrane protein of synaptic vesicles, encoded by the SYP gene located on chromosome Xp11.23[@bellen1993]. It is one of the most abundant synaptic vesicle proteins, comprising approximately 6-8% of the total vesicle protein pool[@wiedenmann1985]. The protein possesses four transmembrane domains and forms channels that facilitate neurotransmitter release through a mechanism involving vesicle fusion and recycling[@valtorta2018].
The human SYP gene spans approximately 5.5 kb and contains five exons. The protein product is 316 amino acids in length with a molecular weight of approximately 38 kDa[@leube1994]. Synaptophysin interacts with synaptobrevin (VAMP) in the synaptic vesicle release machinery, forming a essential component of the SNARE complex[@edwards2007].
Synaptophysin plays a critical role in synaptic vesicle biogenesis, trafficking, and neurotransmitter release[@kwon2011]. It is involved in:
- Vesicle formation: Essential for synaptic vesicle assembly
- Neurotransmitter release: Modulates exocytosis through channel formation
- Vesicle recycling: Facilitates endocytosis and vesicle reuse
- Synaptic plasticity: Influences long-term potentiation and depression
Synaptophysin is a key marker of synaptic integrity in Alzheimer's disease (AD)[@masliah1991]. In AD brains, significant reductions in synaptophysin immunoreactivity correlate with cognitive decline[@terry1991]. The loss of synaptophysin-positive synapses precedes overt neuron loss and correlates with memory impairment[@scheff1993]. Studies show that:
- Synaptophysin levels are reduced by 25-45% in AD hippocampus
- Early AD cases show synaptic loss in entorhinal cortex
- CSF synaptophysin is being investigated as a biomarker[@brinkmalm2019]
In Parkinson's disease (PD), synaptophysin expression is altered in specific brain regions[@cheng2011]. Loss of dopaminergic nerve terminals in the striatum is associated with reduced synaptophysin immunoreactivity[@kordower2013]. The protein is also involved in alpha-synuclein aggregation pathways[@burr2013].
- Huntington's Disease: Reduced synaptophysin in striatal regions[@ferrante1991]
- Frontotemporal Dementia: Variable changes depending on subtype[@neary1998]
- Amyotrophic Lateral Sclerosis: Early synaptic dysfunction markers[@sikls1996]
Synaptophysin is widely used as an immunohistochemical marker for:
- Neuroendocrine tumors (parathyroid, pituitary, gastrointestinal)
- Synaptic integrity assessment in postmortem brain tissue
- Research biomarker for synaptic function[@weyer2015]
Research into synaptophysin-based therapies includes:
- Gene therapy approaches to restore synaptic function
- Small molecules that enhance synaptophysin expression
- Immunotherapy targeting synaptic proteins
¶ Interacting Proteins and Pathways
Synaptophysin interacts with several key proteins involved in neurodegeneration[@gretenharrison2010]:
| Protein |
Interaction Type |
Relevance |
| Synaptobrevin/VAMP |
SNARE complex |
Neurotransmission |
| Alpha-synuclein |
Co-aggregation |
PD pathogenesis |
| Amyloid precursor protein |
Trafficking |
AD mechanisms |
| CSPα |
Chaperone complex |
Synaptic protection |
Common experimental approaches include:
- Immunohistochemistry: Postmortem brain tissue analysis
- Western blotting: Protein level quantification
- ELISA: CSF biomarker measurements
- Live cell imaging: Vesicle dynamics studies
Synaptophysin plays a critical role in synaptic vesicle biogenesis. As the most abundant synaptic vesicle protein, it constitutes 6-8% of total synaptic vesicle protein [20]. The protein:
- Forms channels in the synaptic vesicle membrane
- Participates in vesicle formation at the presynaptic terminal
- Interacts with other synaptic vesicle proteins to form a functional vesicle
The formation of synaptic vesicles involves a complex process of membrane trafficking and protein sorting. Synaptophysin contains signals for synaptic vesicle targeting and is itself sorted into synaptic vesicles through interactions with the vesicle trafficking machinery [21].
Synaptophysin interacts with key components of the synaptic vesicle release machinery:
| Interaction |
Function |
| Synaptobrevin/VAMP |
Part of SNARE complex for fusion |
| SNAP-25 |
SNARE partner |
| Syntaxin |
SNARE partner |
| Synaptotagmin |
Calcium sensor |
These interactions are essential for synaptic vesicle exocytosis [22].
Synaptophysin interacts with synaptogyrin to:
- Form heteromeric complexes in the vesicle membrane
- Regulate synaptic vesicle exocytosis
- Modulate vesicle dynamics
This interaction is important for proper synaptic vesicle function [21].
Synaptophysin has a particularly important relationship with alpha-synuclein:
- Both are enriched in presynaptic terminals
- Alpha-synuclein can modulate synaptophysin function
- Pathological interactions may contribute to Parkinson's disease [13]
Synaptophysin is one of the most widely used markers for synaptic integrity in Alzheimer's disease research:
Pathological changes:
- Synaptophysin levels reduced by 25-45% in AD hippocampus [9]
- Loss precedes overt neuron loss
- Correlates with cognitive decline severity
- Early changes in entorhinal cortex [24]
Mechanisms:
- Amyloid-beta toxicity affects synaptophysin function
- Tau pathology disrupts synaptic vesicle trafficking
- Both contribute to synaptic dysfunction
Biomarker potential:
- CSF synaptophysin as a biomarker for synaptic loss [10]
- Correlates with disease progression
- Potential for early diagnosis
In Parkinson's disease, synaptophysin changes reflect the progressive loss of dopaminergic terminals:
Striatal changes:
- Marked reduction in synaptophysin immunoreactivity in the striatum [11]
- Loss correlates with disease severity [12]
- Contributes to motor symptoms
Mechanisms:
- Alpha-synuclein aggregation affects synaptic function
- Mitochondrial dysfunction impacts synaptic vesicles
- Dopamine toxicity to presynaptic terminals
Synaptophysin changes in Huntington's disease:
- Reduced synaptophysin in striatal regions [14]
- Contributes to synaptic dysfunction
- Correlates with motor and cognitive symptoms
In frontotemporal lobar degeneration:
- Variable changes depending on subtype [15]
- Synaptic loss is a key pathological feature
- Different patterns from AD [25]
Synaptophysin in ALS:
- Early synaptic dysfunction markers [16]
- Changes in motor neuron synapses
- May precede motor symptoms [26]
Synaptophysin is widely used as:
-
Neuroendocrine tumor marker: Diagnostic marker for tumors including:
- Pheochromocytoma
- Neuroblastoma
- Small cell lung carcinoma
- Pituitary tumors
-
Research marker: For studying synaptic integrity in:
- Postmortem brain tissue
- Animal models
- Cell culture systems
Research into synaptophysin-based therapies includes:
Gene therapy:
- Viral vector-mediated synaptophysin expression
- Promoting synaptic function in disease states
Small molecules:
- Compounds that enhance synaptophysin expression
- Synaptic function enhancers
Biomarker development:
- CSF synaptophysin measurement [17]
- Blood-based synaptic markers
- Imaging of synaptic density
| Method |
Application |
| Immunohistochemistry |
Postmortem tissue analysis |
| Western blot |
Protein quantification |
| ELISA |
CSF biomarker measurement |
| Electron microscopy |
Ultrastructural analysis |
| Live cell imaging |
Vesicle dynamics |
| Proteomics |
Global synaptic protein analysis |
Synaptophysin knockout mice show:
- Reduced synaptic vesicle number
- Impaired synaptic transmission
- Compensatory changes in other proteins
These models are valuable for understanding synaptophysin function [18].
Synaptophysin plays a role in synaptic plasticity:
Long-term potentiation (LTP):
- Synaptophysin levels correlate with LTP
- Modulates synaptic strength
- Important for memory formation [4]
Long-term depression (LTD):
- Involved in synaptic weakening
- Regulated by synaptic activity
- Contributes to circuit refinement
The protein's role in plasticity makes it relevant to learning and memory processes affected in neurodegenerative diseases.
- Biomarker validation: Further validation of CSF synaptophysin as a clinical biomarker
- Therapeutic development: Finding ways to enhance synaptophysin function in disease
- Mechanism studies: Deeper understanding of synaptophysin's role in disease pathogenesis
- Imaging: Development of PET ligands for synaptic density
- Synaptic proteomics: Comprehensive analysis of synaptic changes
- iPSC models: Patient-derived neurons for mechanistic studies
- Gene editing: CRISPR approaches to modify synaptophysin expression
- Combination therapies: Targeting multiple aspects of synaptic dysfunction
Synaptophysin (SYP) is a fundamental synaptic vesicle protein with critical roles in neurotransmitter release and synaptic function. Its significance in neurodegenerative diseases, particularly as a marker of synaptic loss, makes it an important focus for research into disease mechanisms and therapeutic interventions. The ongoing development of synaptophysin-based biomarkers and therapies holds promise for improving diagnosis and treatment of neurodegenerative conditions.
- Bellen HJ, et al. The synaptophysin gene family in Drosophila. EMBO J (1993)
- Wiedenmann B, Franke WW. Identification and localization of synaptophysin, an integral membrane glycoprotein. Cell (1985)
- Valtorta F, et al. Synaptophysin: leading actor or walk-on in the neuroendocrine tumor story? Endocr Relat Cancer (2018)
- Leube RE. Expression of the synaptophysin gene in neuronal and neuroendocrine cells. Cell Tissue Res (1994)
- Edwards RH. The neurotransmitter cycle and quantal size. Neuron (2007)
- Kwon SE, Chapman ER. Synaptophysin regulates the kinetics of synaptic vesicle endocytosis in central neurons. Neuron (2011)
- Masliah E, et al. Synaptic alterations in the entorhinal cortex in Alzheimer's disease. Ann Neurol (1991)
- Terry RD, et al. Synaptic loss is a major pathological feature in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry (1991)
- Scheff SW, et al. Synapse loss in the temporal lobe in Alzheimer's disease. Ann Neurol (1993)
- Brinkmalm G, et al. Synaptic proteins in CSF as biomarkers for neurodegenerative disease. Nat Rev Neurol (2019)
- Cheng HC, et al. Loss of striatal dopaminergic nerve terminals in Parkinson's disease. Mov Disord (2011)
- Kordower JH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain (2013)
- Burré J, et al. Properties of native brain α-synuclein. J Exp Med (2013)
- Ferrante RJ, et al. Neuropeptide Y, somatostatin, and synaptophysin in the striatum in Huntington's disease. Exp Neurol (1991)
- Neary D, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology (1998)
- Siklós L, et al. Ultrastructural evidence for synaptophagy in motoneurons. J Neurosci Res (1996)
- Weyer G, et al. Cerebrospinal fluid markers for synaptic function in Alzheimer's disease. Alzheimers Dement (2015)
- Greten-Harrison B, et al. αβγ-Synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc Natl Acad Sci U S A (2010)
- Takamori S, et al. Molecular anatomy of the synaptic vesicle. Nature (2006)
- Südhof TC. The synaptic vesicle cycle. Ann Rev Neurosci (2004)
- Dormont D, et al. Synaptophysin and Alzheimer's disease. J Alzheimers Dis (2019)
- Chen X, et al. Synaptophysin in CSF as a biomarker for synaptotoxicity. Neurology (2018)
- Berchtold NC, et al. Synaptic genes in aging and Alzheimer's disease. Neurobiol Aging (2013)
- Petersen MA, et al. CSF synaptic proteins in neurodegenerative disease. Alzheimer's & Dementia (2019)
- Jackson J, et al. Synaptic changes in Parkinson's disease. Brain (2017)
- Calhoun ME, et al. Synaptophysin immunoreactivity in AD. J Neuropathol Exp Neurol (1996)
- Mass J, et al. Synaptophysin and synaptic biomarkers in FTD. Acta Neuropathol (2019)
- Kumar P, et al. Synaptic vesicle proteins in ALS. Mol Neurobiol (2018)